Mark Tarnopolsky

Co-Applicant
Professor of Pediatrics and Medicine, Director of Neuromuscular and Neurometabolic Clinic, McMaster University Medical Center
CEO/CSO Exerkine Corporation
NMD4C Involvement: Pillar 1: Preclinical Science
Email MarkResearch Interests: Mitochondrial disease, Neurogenetic diagnostics, Neurometabolic disorders, MD therapeutics, Aging/sarcopenia, Obesity
Academic web profileGoogle Scholar profile
Biography
Dr. Tarnopolsky is a neuromuscular and neurometabolic clinician-scientist who received an MD and PhD (Cell Biology and Metabolism) from McMaster University. He currently holds an endowed chair from McMaster Children’s Hospital Foundation in the area of neuromuscular and neurometabolic genetic disorders and follows over 1500 patients with myopathies, mitochondrial disorders and other neurogenetic disorders. He has published over 500 peer reviewed papers and has an h-index of 142. His research focuses on pharmacological, nutraceutical and exercise therapies for neuromuscular and neurometabolic disorders, aging, obesity and other disorders that affect the mitochondria and muscle function. He is the founder, CEO and CSO of Exerkine Corporation which is a bio-technology/nutraceutical company developing therapies for aging, obesity, muscular dystrophy and mitochondrial disorders.
Recent Publications
Mikhail, AI, Ng, SY, Xhuti, D, Lesinski, MA, Chhor, J, Deguise, MO et al.. Skeletal Muscle Mitochondrial and Autophagic Dysregulation Are Modifiable in Spinal Muscular Atrophy. J Cachexia Sarcopenia Muscle. 2025.16 (1)e13701 PMID:39901351
Ivaniuk, A, Anselm, IA, Bowen, A, Cohen, BH, Eminoglu, FT, Estrella, J et al.. Characterization of Factors Associated With Death in Deceased Patients With Mitochondrial Disorders: A Multicenter Cross-Sectional Survey. Neurology. 2025.104 (4)e209779 PMID:39883904
Nilsson, MI, Xhuti, D, de Maat, NM, Hettinga, BP, Tarnopolsky, MA. Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management. Nutrients. 2024.16 (24) PMID:39771028
Antonio, J, Brown, AF, Candow, DG, Chilibeck, PD, Ellery, SJ, Forbes, SC et al.. Part II. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?. J Int Soc Sports Nutr. 2025.22 (1)2441760 PMID:39720835
Karaa, A, Bertini, E, Carelli, V, Cohen, B, Ennes, GM, Falk, MJ et al.. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet J Rare Dis. 2024.19 (1)431 PMID:39574155
Kishnani, PS, Byrne, BJ, Claeys, KG, DĂaz-Manera, J, Dimachkie, MM, Kushlaf, H et al.. Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease. J Patient Rep Outcomes. 2024.8 (1)132 PMID:39535661
McMillan, HJ, Gonorazky, H, Campbell, C, Chrestian, N, Crone, M, Dowling, JJ et al.. Equitable Access to Disease-Modifying Therapies for Canadian Children with SMA and Four SMN2 Copies. Can J Neurol Sci. 2024. 1-3 PMID:39534980
Al-Tawari, J, Tarnopolsky, MA, Burneo, JG, Budhram, A. Lack of Comprehensive Neural Antibody Testing: A Contributor to Diagnostic Delay in Autoimmune Encephalitis. Can J Neurol Sci. 2024. 1-4 PMID:39494937
Mak, G, Tarnopolsky, M, Lu, JQ. Secondary mitochondrial dysfunction across the spectrum of hereditary and acquired muscle disorders. Mitochondrion. 2024.78 101945 PMID:39134108
Brady, L, Yadav, R, Edmondson, AC, Tarnopolsky, M. Missense variant in PIGM associated with severe cystic encephalomalacia and portal vein thrombosis: Phenotypic and genotypic expansion of the glycosylphosphatidylinositol biosynthesis defect-1 (GPIBD1). Am J Med Genet A. 2024.194 (12)e63833 PMID:39119839
See more on PubMed